PRINCETON, NJ – Mar. 12, 2018 – Certara today announced that it is partnering with faculty at the UNC Eshelman School of Pharmacy to launch the Model-informed Drug Development (MIDD) Gran Prix at the 2018 American Society for Clinical Pharmacology & Therapeutics (ASCPT) Annual Meeting.
Achieving a pathway-based approach to more efficient chemical risk assessment.
In this webinar, Dr. Tom Snowden demonstrated why reduction methods are a potent and necessary tool in the modeler’s arsenal, how reduction methods can be applied to QSP models, and how model reduction can be used to extract scientific and business insights from complex models.
PRINCETON, NJ – July 25, 2017 – Certara today announced that Professor Piet van der Graaf, PharmD, PhD, vice president and head of Certara QSP, is co-chairing the NIH workshop entitled “QSP and Drug Discovery: Filling the Gaps in Current Models of the R&D Process for Neurotherapeutics.”
PRINCETON, NJ – Jan. 25, 2017 – Certara today announced that it is launching a Quantitative Systems Pharmacology (QSP) Immunogenicity Consortium. Modeled after Certara’s highly successful Simcyp Consortium, the QSP Immunogenicity Consortium brings together leading biopharmaceutical companies in a pre-competitive environment to cooperatively develop an Immunogenicity Simulator.
A selection of short essays from our blog, written to empower our customers with modeling and simulation (M&S) and regulatory writing solutions in order to help them solve the toughest drug development problems. Certara staff contributions range in topic from pharmacometrics to systems biology to the growing importance of regulatory writing and sharing clinical trial results.
A primary cause of failures in pharmaceutical research and development (R&D) has been attributed to lack of efficacy,1 suggesting inadequate understanding in therapeutic targets’ biology and their relevance to disease progression or modulation. Quantitative systems pharmacology (QSP) has the promise of increasing the probability of success in R&D by bridging scientific gaps between disciplines to enable … Continued
Information on the developmental changes in biliary excretion (BE) of drugs is sparse. The aims of this study were to collate literature data on the pharmacokinetics of biliary excretion of drugs used in pediatrics and to apply a physiologically-based pharmacokinetic (PBPK) model to predict their systemic clearance (CL) with a view to elucidating age-related changes … Continued
